Next Phase Newsletter

Established in 2017, a venture capital fund is a $60M+ venture capital partnership and a new addition to its sister fund. The firm is focused on companies that contribute to the delivery of “Delightful Moments”, in other words technologies that enhance the human experience and contribute to their well-being. For initial investment, the firm will invest $100-500K and will reserve some funds for follow-on investment. The firm invests mainly in Seed to Series A rounds and often acts as the first institutional investor. The firm has offices in USA and Western Europe, and expanded into Western Europe in early 2019. Currently, the firm is focused on investing in companies based in the USA and Western Europe.

The firm is interested in companies dedicated to the “technological vectors of happiness”. Such technologies include genetics, microbiome, personal pharmaceuticals/diagnostics, VR/AR, consumer-facing medtech or digital health technologies, etc. Initially, the firm did not invest in traditional biopharmaceuticals or medical devices, but the firm has expanded their interests and now actively seeking opportunities in therapeutics and devices with a focus on early-stage, pre-IND companies.

The firm is open to working with all types of management teams and has no specific management requirements. They could lead the round at seed stage but typically syndicate with other investors for Series A. The firm will take an active role in supporting their companies with needed guidance and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A private investment firm founded in 2016 is based in New York City, NY and in Asia. The firm’s limited partners include institutional investors from US and China. Currently the firm is investing from its Phase I US$180 million fund into the healthcare sector. Typical equity investments range from US$5-10 million in businesses from Series A to pre-IPO and public traded companies. The firm is open to leading or following a syndicated round. The firm is now seeking opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and healthcare IT and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefers clinical-stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observership on a case-by-case basis.

The firm is the newly established investment funding arm of a West Coast-based health system. The health system operates 28 hospitals across 6 states. The firm’s objectives include fostering the commercialization of internal ideas as well as external innovation. The firm made its first investment in September 2020, and expect to close 2 more investments in the next 3 months. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.

The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the health system’s strategic position in the future. Areas of interest include improving the ratings and member retention in our Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.

The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital firm based in Vancouver, Canada and actively invests in health technology, sports technology, fitness, and nutrition businesses. The firm is an early-stage investor and focuses on investing in Seed to Series A rounds. The firm makes initial investments up to $100K through equity or convertible notes and will make 2-4 investments per year. The firm is raising a new fund that will focus on companies along the Pacific Coast of the USA and across Canada, but currently focuses on investing in Canada-based companies. With the launch of the new venture fund, the firm will invest up to $500k in first rounds.

The firm is dedicated to investing in preventative health and proactive technology solutions that optimize health, activity and longevity. As social impact and technology investors, the firm is committed to the development of technologies, products and services that both enhance and promote an individual’s ability to stay optimally healthy and active over an entire lifetime. The firm focuses on innovative health technologies including digital health, mobile health, sport technology, wearable technology, and those that help with chronic disease management and corporate wellness initiatives. The firm is very interested in consumer-facing technologies that can enhance health and wellness, quality of care, as well as technologies that could be used in developing preventative health strategies and solutions. The firm does not have minimum revenue requirements and will consider companies in their earliest stages as long as they demonstrate high growth potential. The firm

will not consider therapeutics or diagnostic companies. Medical devices subject to a 510k approval process will be considered.

The firm seeks to invest in private companies developing technologies that positively impact health and wellness. The firm can work with all types of management teams with flexibility, although strong experience and a successful track record is a plus. The firm works closely with their portfolio companies and will provide needed expertise, including access to an international network of strategic advisors to support their growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A firm with offices in USA and Asia is currently making investments into promising private healthcare companies as well as promising public healthcare companies. The firm invests exclusively in the healthcare sector; the firm invests primarily in the USA and Greater China but will also invest in other regions such as Europe and ASEAN countries. Within China, the firm makes growth investments in companies but also find some companies with interesting and innovative product in recent years there; in the USA and other regions, The firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $20-50m, though larger investments are of interest as well; the firm makes investments of typically $5-20 million The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, gene therapy, cell therapy, are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. Healthcare AI is an area we are interested and exploring. One of their funds focuses on early-stage opportunities in biotech; though from the main fund, the firm makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, the firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm based in Western Europe invests exclusively in the life science space and is currently investing out of their first fund. The firm looks to invest in early-stage life science companies crossing all sectors and is opportunistic in terms of subsector and indication. The firm focuses on Pre-Seed, Seed, Series A and Series B investments and investments are in the form of equity. The firm makes investments ranging from $50K to $3M per round. The firm will consider opportunities globally.

In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, digital health, medical device and femtech sectors. The firm is open to pre-clinical companies and all three stages of medical devices. The firm has a broad investment interest and is opportunistic in terms of sub-sectors and indications.

The firm looks for all types of management teams, however a proven track record is a plus. The firm is open to both leading and co-investing. If the firm leads, they seek board seat representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital Company based in the USA manages three healthcare and life sciences funds for a combined total of $60 million in assets under management. The firm looks to make equity investments of approximately $500k – $1 million into companies with additional capital reserved for follow on rounds. The firm looks to act as a bridge with its investments between the Seed and Series A round. The firm is also open to syndication with other investors for larger deals. The firm focuses its investments in the Midwest but is open to companies located throughout the US and makes approximately 6-8 investments per year.

The firm has recently launched a new healthcare fund in collaboration with another VC firm, and resulting the firm’s focus has shifted more towards Healthcare IT and Digital Health, with a specific focus on how healthcare delivery has changed during the COVID 19 pandemic. Examples of the subsectors of interest are: remote care, Healthcare IT for hospital efficiency, and response infrastructure systems. The firm is opportunistic in terms of indication.

The firm looks for management teams with domain experience, and is comfortable with working with incomplete or scientific founding teams. The firm prefers to take a board seat into companies following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.